Anthony Cultrara, MD
Otolaryngology · Mount Laurel, NJNPI 1083619860
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Sanofi at 28.7% of the total.
Across 133 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$839
- Optinose US, Inc.$423
- GSK$373
- Regeneron Healthcare Solutions, Inc.$266
- Medtronic$173
- Alk-abello, Inc$157
- plus $690 from 16 others
What the payments were for
- Food & beverage$2,920100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 29 | $839 |
| Optinose US, Inc. | 24 | $423 |
| GSK | 23 | $373 |
| Regeneron Healthcare Solutions, Inc. | 11 | $266 |
| Medtronic(2 entities) | 3 | $173 |
| Alk-abello, Inc | 10 | $157 |
| Inspire Medical Systems, Inc. | 1 | $118 |
| Hikma Pharmaceuticals USA | 4 | $94 |
| Aerin Medical Inc. | 4 | $66 |
| CSL Behring | 3 | $60 |
| Acclarent, Inc | 4 | $59 |
| Grifols USA, LLC | 3 | $48 |
| Merck | 3 | $46 |
| KARL Storz Endoscopy-america | 2 | $42 |
| Stryker | 2 | $42 |
| Bard Access Systems, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Intersect ENT, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,920 in reported general payments places this provider in the 75th percentile of 232 otolaryngology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QnaslBeclomethasone Dipropionate | 17 | $7,873 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 26 | $6,791 |
| Pantoprazole Sodium | 336 | $4,090 |
| Ipratropium Bromide | 118 | $3,799 |
| Fluticasone Propionate | 182 | $3,369 |
| Cevimeline Hcl | 22 | $3,201 |
| Famotidine | 241 | $2,793 |
| Mometasone Furoate | 24 | $1,812 |
| Esomeprazole Magnesium | 60 | $1,729 |
| Omeprazole | 158 | $1,714 |
| Montelukast Sodium | 114 | $1,591 |
| Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid | 15 | $1,556 |
| Fluocinolone Acetonide Oil | 47 | $1,492 |
| Ofloxacin | 35 | $1,172 |
| Amitriptyline Hcl | 14 | $784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Qnasl | $17 | $7,87317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 232 otolaryngology providers in New Jersey.
Other otolaryngology in Mount Laurel
- Saurin SanghviMount Laurel$7K
- Nishant ReddyEast Windsor$133K
- Giant LinFlorham Park$25K
- Samir ShahVoorhees$16K
- Brian BensonHackensack$14K
- Andrew BlitzerHackensack$9K
- Ahmad MahmoudClifton$9K
- Jean EloyNewark$8K
- Ramtin KassirWayne$8K
- Wayne HsuehNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.